Safety concerns with current treatments for psoriasis in the elderly

References

• Grozdev I, Korman N, Tsankov N. Psoriasis as a systemic disease. Clin Dermatol. 2014;32:343–350.
   PubMed Web of Science ®Google Scholar
• Di Lernia V, Ficarelli E. Current therapeutic approaches of psoriasis are affected by age at disease onset. J Dermatolog Treat. 2014;25:15–17.
   PubMed Web of Science ®Google Scholar
• Grozdev IS, Van Voorhees AS, Gottlieb AB, et al. Psoriasis in the elderly: from the medical board of the national psoriasis foundation. J Am Acad Dermatol. 2011;65:537–545.
   PubMed Web of Science ®Google Scholar
• Phan C, Sigal ML, Estève E, et al. Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis. J Eur Acad Dermatol Venereol. 2016;30:78–82.
   PubMed Web of Science ®Google Scholar
• Balato N, Patruno C, Napolitano M, et al. Managing moderate-to-severe psoriasis in the elderly. Drugs Aging. 2014;31:233–238.
   PubMed Web of Science ®Google Scholar
• Fernandez-Torres RM, Paradela S, Fonseca E. Psoriasis in patients older than 65 years. A comparative study with younger adult psoriatic patients. J Nutr Health Aging. 2012;16:586–591.
   PubMed Web of Science ®Google Scholar
• Caiazzo G, Fabbrocini G, Di Caprio R, et al. Psoriasis, cardiovascular events, and biologics: lights and shadows. Front Immunol. 2018;9:1668.
   PubMed Web of Science ®Google Scholar
• Kratzsch D, Treudler R. Dermatologic therapy in geriatric patients. J Dtsch Dermatol Ges. 2014;12:653–663.
   PubMed Web of Science ®Google Scholar
• Caruso C, Buffa S, Candore G, et al. Mechanisms of immunosenescence. Immun Ageing. 2009;22:6–10.
   Google Scholar
• Kostović K, Žužul K, Čeović R, et al. Psoriasis in the mature patient: therapeutic approach in the era of biologics. Clin Dermatol. 2018;36:222–230.
   PubMed Web of Science ®Google Scholar
• Di Lernia V, Goldust M. An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly. Expert Opin Biol Ther. 2018;18:897–903.
   PubMed Web of Science ®Google Scholar
• Kamel JG, Yamauchi PS. Managing mild-to-moderate psoriasis in elderly patients: role of topical treatments. Drugs Aging. 2017;34:583–588.
   PubMed Web of Science ®Google Scholar
• Takeshita J, Gelfand JM, Li P, et al. Psoriasis in the U.S. Medicare population: prevalence, treatment, and factors associated with biologic use. J Invest Dermatol. 2015;135:2955–2963.
   PubMed Web of Science ®Google Scholar
• Ruiz-Villaverde R, Garrido-Colmenero C, Martinez-Peinado CM, et al. Psoriasis in the elderly. Do we know how to manage it? Hong Kong J Dermatol Venereol. 2015;23:175–182.
   Web of Science ®Google Scholar
• Parslew R, Traulsen J. Efficacy and local safety of a calcipotriol/betamethasone dipropionate ointment in elderly patients with psoriasis vulgaris. Eur J Dermatol. 2005;15:37–39.
   PubMed Web of Science ®Google Scholar
• Devaux S, Castela A, Archier E, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26:61–67.
   PubMed Web of Science ®Google Scholar
• Powell Mengeaud V, Dautezac-Vieu C, Josse G, et al. Prevalence of dermatoporosis in elderly French hospital in-patients: a cross-sectional study. Br J Dermatol. 2012;166:440–469.
   PubMed Web of Science ®Google Scholar
• Zhang P, Wu MX. A clinical review of phototherapy for psoriasis. Lasers Med Sci. 2018;33:173–180.
   PubMed Web of Science ®Google Scholar
• Gloor M, Scherotzke A. Age dependence of ultraviolet light-induced erythema following narrow-band UVB exposure. Photodermatol Photoimmunol Photomed. 2002;18:121–126.
   PubMed Web of Science ®Google Scholar
• Powell JB, Gach JE. Phototherapy in the elderly. Clin Exp Dermatol. 2015;40:605–610.
   PubMed Web of Science ®Google Scholar
• Bulur I, Erdogan HK, Aksu AE, et al. The efficacy and safety of phototherapy in geriatric patients: a retrospective study. An Bras Dermatol. 2018;93:33–38.
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–850.
   PubMed Web of Science ®Google Scholar
• Maresca B, Lembo S, Ayala F, et al. Understanding the role of haptoglobin in psoriasis: effects of ultraviolet B. Clin Exp Dermatol. 2016;41:74–80.
   PubMed Web of Science ®Google Scholar
• Martin JA, Laube S, Edwards C, et al. Rate of acute adverse events for narrow-band UVB and Psoralen-UVA phototherapy. Photodermatol Photoimmunol Photomed. 2007;23:68–72.
   PubMed Web of Science ®Google Scholar
• Nadai M, Katoh M. Changes in pharmacokinetics in elderly patients. Nihon Rinsho. 2013;71:999–1003.
   PubMedGoogle Scholar
• Bressler R, Bahl JJ. Principles of drug therapy for the elderly patient. Mayo Clin Proc. 2003;78:1564–1577.
   PubMed Web of Science ®Google Scholar
• Bagherani N, Smoller BR. Effectiveness of azathioprine pulse therapy in prolonging remission of psoriasis. Dermatol Ther. 2017;30:1.
   Web of Science ®Google Scholar
• Mahbub MS, Khondker L, Khan SI, et al. Comparative efficacy of hydroxyurea and methotrexate in treating psoriasis. Mymensingh Med J. 2013;22:116–130.
   PubMedGoogle Scholar
• Dai Q, Xu L, Yu X. Efficacy and safety of leflunomide in psoriatic arthritis treatment: a single-arm meta-analysis. Int J Rheum Dis. 2019;22:1498–1505.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Ellis CN, Siegel MT, et al. Sulfasalazine improves psoriasis: a double-blind analysis. Arch Dermatol. 1990;126:487–493.
   PubMedGoogle Scholar
• Malecic N, Young H. Tacrolimus for the management of psoriasis: clinical utility and place in therapy. Psoriasis (Auckl). 2016;6:153–163.
   PubMedGoogle Scholar
• Sherer DW, Lebwohl MG. 6-thioguanine in the treatment of psoriasis: a case report and literature review. J Cutan Med Surg. 2002;6:546–550.
   PubMed Web of Science ®Google Scholar
• Fairris GM, Dewhurst AG, White JE, et al. Methotrexate dosage in patients aged over 50 with psoriasis. BMJ. 1989;298:801–802.
   PubMed Web of Science ®Google Scholar
• Collins P, Rogers S. The efficacy of methotrexate in psoriasis-a review of 40 cases. Clin Exp Dermatol. 1992;17:257–260.
   PubMed Web of Science ®Google Scholar
• Prodanovich S, Ma F, Taylor JR, et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005;52:262–267.
   PubMed Web of Science ®Google Scholar
• Boffa MJ, Chalmers G. Methotrexate for psoriasis. Clinical and Exper Dermatol. 1996;21:399–408. 6.
   PubMed Web of Science ®Google Scholar
• Piaserico S, Conti A, Lo Console F, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol. 2014;94:293–297.
   PubMed Web of Science ®Google Scholar
• Ohtsuki M, Nakagawa H, Sugai J, et al. Long-term continuous versus intermittent cyclosporin: therapy for psoriasis. J Dermatol. 2003;30:290–298.
   PubMed Web of Science ®Google Scholar
• Heydendael VM, Spuls PI, Ten Berge IJ, et al. Cyclosporine trough levels: is monitoring necessary during short-term treatment in psoriasis. Br J Dermatol. 2002;147:122–129.
   PubMed Web of Science ®Google Scholar
• Geiger JM. Efficacy of acitretin in severe psoriasis. Skin Therapy Lett. 2003;8:1–3.
   PubMedGoogle Scholar
• Bhutani T, Koo J. A review of the chemopreventative effects of oral retinoids for internal neoplasms. J Drugs Dermatol. 2011;10:1292–1298.
   PubMed Web of Science ®Google Scholar
• Wong JW, Koo JYM. The safety of systemic treatments that can be used for geriatric psoriasis patients: a review. Dermatol Res Pract. 2012;36:74–75.
   Google Scholar
• Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch of Dermatol. 2012;148:95–102.
   PubMed Web of Science ®Google Scholar
• Butler DC, Koo JYM. Psoriasis therapy in the geriatric population. In: Chang ALS, editor. Advances in Geriatric Dermatology. New York, NY: Springer; 2015. p. 65–69.
   Google Scholar
• Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159:842–855.
   PubMed Web of Science ®Google Scholar
• Crowley J, Thaci D, Joly P, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for >/=156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77:310–317.
   PubMed Web of Science ®Google Scholar
• Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37–49.
   PubMed Web of Science ®Google Scholar
• Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173:1387–1399.
   PubMed Web of Science ®Google Scholar
• Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75:1065–1073.
   PubMed Web of Science ®Google Scholar
• Schafer PH, Chen P, Fang L, et al. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1). J Immunol Res. 2015;90:6349.
   Google Scholar
• Cutolo M, Myerson GE, Fleischmann RM, et al. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol. 2016;43:1724–1734.
   PubMed Web of Science ®Google Scholar
• Rowietz U, Altmeyer P, Bieber T, et al. Treatment of psoriasis with fumaric acid esters (Fumaderm). J Dtsch Dermatol Ges. 2007;5:716–717.
   PubMedGoogle Scholar
• Reich K, Thacßi D, Mrowietz U, et al. Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis – a retrospective study (FUTURE). J Dtsch Dermatol Ges. 2009;7:603–610.
   PubMed Web of Science ®Google Scholar
• Heelan K, Markham T. Fumaric acid esters as a suitable first-line treatment for severe psoriasis: an Irish experience. Clin Exp Dermatol. 2012;37:793–795.
   PubMed Web of Science ®Google Scholar
• Burden-Teh E, Lam M, Cohen S. Fumaric acid esters to treat psoriasis: experience in a U.K. teaching hospital. J Am Acad Dermatol. 2013;68(Suppl. 1):AB52.
   Google Scholar
• Carboni I, De Felice C, De Simoni I, et al. Fumaric acid esters in the treatment of psoriasis: an Italian experience. J Dermatolog Treat. 2004;15:23–26.
   PubMedGoogle Scholar
• Balato A, Schiattarella M, Di Caprio R, et al. Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway. J Eur Acad Dermatol Venereol. 2014;28:1016–1024.
   PubMed Web of Science ®Google Scholar
• Di Costanzo L, Scala E, Caiazzo G, et al. Possible role of BMP-4 in the hyper-pigmentation of psoriatic plaques after anti-TNF-α treatment. Exp Ther Med. 2019;18:4120–4124.
   PubMed Web of Science ®Google Scholar
• Balato A, Scala E, Balato N, et al. Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders. Expert Opin Biol Ther. 2017;17:1363–1374.
   PubMed Web of Science ®Google Scholar
• Fernández-Ruiz M, Aguado JM. Risk of infection associated with anti-TNF-α therapy. Expert Rev Anti Infect Ther. 2018;16:939–956.
   PubMed Web of Science ®Google Scholar
• Reich K, Wozel G, Zheng H, et al. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). Br J Dermatol. 2013;168:1325–1334.
   PubMed Web of Science ®Google Scholar
• Militello G, Xia A, Stevens SR, et al. Etanercept for the treatment of psoriasis in the elderly. J Am Acad Dermatol. 2006;55:517–519.
   PubMed Web of Science ®Google Scholar
• Menter A, Gordon KB, Leonardi CL, et al. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010;63:448–456.
   PubMed Web of Science ®Google Scholar
• Torrente-Segarra V, Fernandez Prada M, Expósito Moliner R, et al. How elderly rheumatoid arthritis patients respond at one year of treatment with certolizumab pegol. Rheumatol Int. 2019;39:395–398.
   PubMedGoogle Scholar
• Lebwohl M, Blauvelt A, Paul C, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol. 2018;79:266–276.e5.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Blauvelt A, Thaçi D, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol. 2018;79:302–314.e6.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Pavlidis A, Dattola A, et al. Efficacy and safety of infliximab in psoriatic patients over the age of 65. Expert Opin Drug Saf. 2016;15:1459–1462.
   PubMed Web of Science ®Google Scholar
• Esposito M, Giunta A, Mazzotta A, et al. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Dermatology. 2012;225:312–319.
   PubMed Web of Science ®Google Scholar
• Garber C, Plotnikova N, Au SC, et al. Biologic and conventional systemic therapies show similar safety and efficacy in elderly and adult patients with moderate to severe psoriasis. J Drugs Dermatol. 2015;14:846–852.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Sarzi-Puttini P, Botsios C, et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev. 2012;12:225–229.
   PubMed Web of Science ®Google Scholar
• Ricceri F, Bardazzi F, Chiricozzi A, et al. Elderly psoriatic patients under biological therapies: an Italian experience. J Eur Acad Dermatol Venereol. 2019;33:143–146.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31:774–790.
   PubMed Web of Science ®Google Scholar
• Schmitt J, Rosumeck S, Thomaschewski G, et al. Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol. 2014;170:274–303.
   PubMed Web of Science ®Google Scholar
• Momose M, Asahina A, Hayashi M, et al. Biologic treatments for elderly patients with psoriasis. J Dermatol. 2017;44:1020–1023.
   PubMed Web of Science ®Google Scholar
• Megna M, Napolitano M, Balato N, et al. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period. Clin Exp Dermatol. 2016;41:564–566.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Umezawa Y, Fukuchi O, et al. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis. J Dermatol. 2014;41:974–980.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med. 2014;371:326–338.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate‐to‐severe plaque psoriasis. N Engl J Med. 2016;375:345–356.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate‐to‐severe psoriasis (UNCOVER‐2 and UNCOVER‐3): results from two phase 3 randomised trials. Lancet. 2015;386:541–551.
   PubMed Web of Science ®Google Scholar
• Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis. Br J Dermatol. 2016;175:273–286.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Burlando M, Caldarola G, et al. Ixekizumab effectiveness and safety in the treatment of moderate-to-severe plaque psoriasis: a multicenter, retrospective observational study. Am J Clin Dermatol. 2019. DOI:10.1007/s40257-019-00490-2.
   PubMed Web of Science ®Google Scholar
• Raimondo A, Lembo S, Caiazzo G, et al. Anti IL-17 therapy rapidly decreases osteoclast activity in psoriatic patients: a novel quality in addition to its efficacy and safety. G Ital Dermatol Venereol. 2018. DOI:10.23736/S0392-0488.18.06175-8.
   Google Scholar
• Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017;76:60–69.
   PubMed Web of Science ®Google Scholar
• Körber A, Papavassilis C, Bhosekar V, et al. Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies. Drugs Aging. 2018;35:135–144.
   PubMed Web of Science ®Google Scholar
• Ricceri F, Pescitelli L, Lazzeri L, et al. First case of secukinumab successful therapy in a very elderly psoriatic patient. Dermatol Ther. 2018;31:e12668.
   PubMed Web of Science ®Google Scholar
• Medical letter data on file. Ely Lilly.
   Google Scholar
• Megna M, Cinelli E, Balato A, et al. Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period. J Eur Acad Dermatol Venereol. 2019. doi: 10.1111/jdv.16063.
   Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318–1328.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Menter A, Yamauchi P, et al. Brodalumab in patients with psoriasis ages <65 and 65 years: 120-week findings from two phase 3 studies. J Am Acad Dermatol. 2019;81(Suppl. 1):AB176.
   Google Scholar
• Galluzzo M, D’Adamio S, Massaro A, et al. Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date. Clin Cosmet Investig Dermatol. 2019;12:311–321.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Papp KA, Marangell LB, et al. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018;78:81–89.e5.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Romanelli M, Saraceno R, et al. No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents. Expert Opin Drug Saf. 2016;15:1653–1659.
   PubMed Web of Science ®Google Scholar
• Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019;33:1676–1684.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double‐blinded, placebo‐ and active comparator‐controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76:405–417.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double‐blind, placebo‐ and active comparator‐controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76:418–431.
   PubMed Web of Science ®Google Scholar
• Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase 3 NAVIGATE trial. Br J Dermatol. 2018;178:114–123.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394:831–839.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390:276–288.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate‐to‐severe plaque psoriasis (UltIMMa‐1 and UltIMMa‐2): results from two double‐blind, randomised, placebo‐controlled and ustekinumab‐controlled phase 3 trials. Lancet. 2018;392:650–661.
   PubMed Web of Science ®Google Scholar
• [cited 2019 Dec 3]. Available from: https://www.clinicaltrials.gov/
   Google Scholar
• Reich K, Rich P, Maari C, et al. Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study. Br J Dermatol. 2019;181:88–95.
   PubMed Web of Science ®Google Scholar